会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • THERAPEUTIC METHODS FOR NEUROPATHIC PAIN
    • 神经性疼痛的治疗方法
    • WO2008021896A8
    • 2008-12-18
    • PCT/US2007075500
    • 2007-08-08
    • UNIV LOUISIANA STATEBAZAN NICOLAS GCUI JIAN-GUO
    • BAZAN NICOLAS GCUI JIAN-GUO
    • A61K38/00A61K38/17
    • A61K38/1709G01N33/5058G01N2333/4722G01N2800/2842
    • The agrin protein was shown to be important in preventing the development of neuropathic pain, as well as in treating neuropathic pain. Both agrin protein and gene expression were shown to be down-regulated in mammals with neuropathic pain. Increasing either agrin gene expression or protein resulted in a decrease in the development of neuropathic pain. Agrin protein or the C-terminal agrin fragments can be administered in a number of ways, preferably by intrathecal injection. In addition, agrin can be increased by administering a compound shown to affect agrin gene expression or agrin protein concentration, e.g., SCP-I and SCP-Ml (also known as JMM). Agrin protein decrease was shown to be prevented by administering an NMDA receptor antagonist, e.g., MK801. Agrin and a C-terminal agrin fragment also induced phosphorylation of the NMDA receptor subunit NR1 at the serine residue site which led to suppression of neuropathic pain.
    • 证明集聚蛋白对于预防神经性疼痛的发展以及治疗神经性疼痛是重要的。 在神经性疼痛的哺乳动物中,聚集蛋白蛋白和基因表达都显示出下调。 增加集聚蛋白基因表达或蛋白质导致神经性疼痛发展的减少。 可以以多种方式施用Agrin蛋白或C端集聚蛋白片段,优选通过鞘内注射。 另外,通过施用显示影响集聚蛋白基因表达或集聚蛋白浓度的化合物,例如SCP-1和SCP-M1(也称为JMM),可以增加集聚蛋白。 表明通过施用NMDA受体拮抗剂例如MK801可以防止Agrin蛋白减少。 Agrin和C-末端集聚蛋白片段也在丝氨酸残基位点诱导了NMDA受体亚基NR1的磷酸化,导致抑制神经性疼痛。